Overview

Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer

Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
The primary purpose is to determine how effective AG-013736 is in shrinking thyroid cancer that is resistant to radioactive iodine
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer
Treatments:
Axitinib